Patrick B. Mark

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 589 citations · Full text

Urology, Renal Disease, Renal Events +7

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

Matthew M.Y. Lee, Katriona Brooksbank, Kirsty Wetherall et al. · Circulation · 2020 · 417 citations · Full text

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Andrew A. House, Christoph Wanner, Mark J. Sarnak et al. · Kidney International · 2019 · 413 citations · Full text

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Paul R. Kalra, John G.F. Cleland, Mark C. Petrie et al. · The Lancet · 2022 · 344 citations · Full text

Heart Failure, Intravenous Ferric Derisomaltose, Iron Metabolism +3

Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort

Tara Collidge, Peter C. Thomson, Patrick B. Mark et al. · Radiology · 2007 · 318 citations